Nancy J Donovan1, Joseph J Locascio1, Gad A Marshall1, Jennifer Gatchel1, Bernard J Hanseeuw1, Dorene M Rentz1, Keith A Johnson1, Reisa A Sperling1. 1. From the Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston; the Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston; the Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass.; the Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neurosciences, Université Catholique de Louvain, Brussels; the Department of Psychiatry, the Department of Neurology, and the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
Abstract
OBJECTIVE: To understand the role of depressive symptoms in preclinical Alzheimer's disease, it is essential to define their temporal relationship to Alzheimer's proteinopathies in cognitively normal older adults. The study objective was to examine associations of brain amyloid beta and longitudinal measures of depression and depressive symptom clusters in a cognitively normal sample of older adults. METHOD: A total of 270 community-dwelling, cognitively normal elderly individuals underwent baseline Pittsburgh compound B (PiB) positron emission tomography (PET) measures of cortical aggregate amyloid beta and annual assessments with the 30-item Geriatric Depression Scale (GDS). The authors evaluated continuous PiB binding as a predictor of GDS score or GDS cluster, calculated as total scores and mean scores for three GDS item clusters (apathy-anhedonia, dysphoria, and anxiety-concentration), across time (1-5 years; mean=3.8 years) in separate mixed-effects models with backward elimination. Initial predictors included PiB binding, age, sex, Hollingshead score, American National Adult Reading Test (AMNART) score, apolipoprotein E ε4 status, depression history, and their interactions with time. RESULTS: Higher PiB binding predicted accelerated rates of increase in GDS score over time, adjusting for depression history. Higher PiB binding also predicted steeper rates of increase for anxiety-concentration scores, adjusting for depression history and the AMNART score-by-time interaction. In a post hoc model estimating anxiety scores without concentration disturbance items, the PiB binding-by-time interaction remained significant. CONCLUSIONS: Higher amyloid beta burden was associated with increasing anxious-depressive symptoms over time in cognitively normal older individuals. Prior depression history was related to higher but not worsening symptom ratings. These results suggest a direct or indirect association of elevated amyloid beta levels with worsening anxious-depressive symptoms and support the hypothesis that emerging neuropsychiatric symptoms represent an early manifestation of preclinical Alzheimer's disease.
OBJECTIVE: To understand the role of depressive symptoms in preclinical Alzheimer's disease, it is essential to define their temporal relationship to Alzheimer's proteinopathies in cognitively normal older adults. The study objective was to examine associations of brain amyloid beta and longitudinal measures of depression and depressive symptom clusters in a cognitively normal sample of older adults. METHOD: A total of 270 community-dwelling, cognitively normal elderly individuals underwent baseline Pittsburgh compound B (PiB) positron emission tomography (PET) measures of cortical aggregate amyloid beta and annual assessments with the 30-item Geriatric Depression Scale (GDS). The authors evaluated continuous PiB binding as a predictor of GDS score or GDS cluster, calculated as total scores and mean scores for three GDS item clusters (apathy-anhedonia, dysphoria, and anxiety-concentration), across time (1-5 years; mean=3.8 years) in separate mixed-effects models with backward elimination. Initial predictors included PiB binding, age, sex, Hollingshead score, American National Adult Reading Test (AMNART) score, apolipoprotein E ε4 status, depression history, and their interactions with time. RESULTS: Higher PiB binding predicted accelerated rates of increase in GDS score over time, adjusting for depression history. Higher PiB binding also predicted steeper rates of increase for anxiety-concentration scores, adjusting for depression history and the AMNART score-by-time interaction. In a post hoc model estimating anxiety scores without concentration disturbance items, the PiB binding-by-time interaction remained significant. CONCLUSIONS: Higher amyloid beta burden was associated with increasing anxious-depressive symptoms over time in cognitively normal older individuals. Prior depression history was related to higher but not worsening symptom ratings. These results suggest a direct or indirect association of elevated amyloid beta levels with worsening anxious-depressive symptoms and support the hypothesis that emerging neuropsychiatric symptoms represent an early manifestation of preclinical Alzheimer's disease.
Authors: Keith A Johnson; Matt Gregas; John A Becker; Catherine Kinnecom; David H Salat; Erin K Moran; Erin E Smith; Jonathan Rosand; Dorene M Rentz; William E Klunk; Chester A Mathis; Julie C Price; Steven T Dekosky; Alan J Fischman; Steven M Greenberg Journal: Ann Neurol Date: 2007-09 Impact factor: 10.422
Authors: Cyrus A Raji; James T Becker; Nicholas D Tsopelas; Julie C Price; Chester A Mathis; Judith A Saxton; Brian J Lopresti; Jessica A Hoge; Scott K Ziolko; Steven T DeKosky; William E Klunk Journal: J Neurosci Methods Date: 2008-05-16 Impact factor: 2.390
Authors: Dona E C Locke; Amylou C Dueck; Cynthia M Stonnington; David S Knopman; Yonas E Geda; Richard J Caselli Journal: J Clin Psychiatry Date: 2013-12 Impact factor: 4.384
Authors: Yonas E Geda; David S Knopman; David A Mrazek; Gregory A Jicha; Glenn E Smith; Selamawit Negash; Bradley F Boeve; Robert J Ivnik; Ronald C Petersen; V Shane Pankratz; Walter A Rocca Journal: Arch Neurol Date: 2006-03
Authors: Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling Journal: Ann Neurol Date: 2015-12-15 Impact factor: 10.422
Authors: J Alex Becker; Trey Hedden; Jeremy Carmasin; Jacqueline Maye; Dorene M Rentz; Deepti Putcha; Bruce Fischl; Douglas N Greve; Gad A Marshall; Stephen Salloway; Donald Marks; Randy L Buckner; Reisa A Sperling; Keith A Johnson Journal: Ann Neurol Date: 2011-03-17 Impact factor: 10.422
Authors: Ganesh M Babulal; Suzie Chen; Monique M Williams; Jean-Francois Trani; Parul Bakhshi; Grace L Chao; Sarah H Stout; Anne M Fagan; Tammie L S Benzinger; David M Holtzman; John C Morris; Catherine M Roe Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Anna E. Leeuwis; Nick A. Weaver; J. Matthijs Biesbroek; Lieza G. Exalto; Hugo J. Kuijf; Astrid M. Hooghiemstra; Niels D. Prins; Philip Scheltens; Frederik Barkhof; Wiesje M. van der Flier; Geert Jan Biessels Journal: J Psychiatry Neurosci Date: 2019-07-01 Impact factor: 6.186
Authors: Jennifer S Rabin; Zahra Shirzadi; Walter Swardfager; Bradley J MacIntosh; Aaron Schultz; Hyun-Sik Yang; Rachel F Buckley; Jennifer R Gatchel; Dylan Kirn; Jeremy J Pruzin; Trey Hedden; Nir Lipsman; Dorene M Rentz; Sandra E Black; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal Journal: Neurobiol Aging Date: 2020-03-07 Impact factor: 4.673
Authors: Ganesh M Babulal; Catherine M Roe; Sarah H Stout; Ganesh Rajasekar; Julie K Wisch; Tammie L S Benzinger; John C Morris; Beau M Ances Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Sarah K Jachim; Ayumi E Sakamoto; Xu Zhang; Vesselina M Pearsall; Marissa J Schafer; Nathan K LeBrasseur Journal: Ageing Res Rev Date: 2020-08-16 Impact factor: 10.895